Madryn Asset Management

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Calibrate Health, Inc., established in 2020 and based in New York, specializes in digital metabolic health services for sustainable weight loss. The company combines FDA-approved metabolic medications with a comprehensive curriculum and personalized virtual coaching to address the root causes of weight issues and promote long-term behavior change. Calibrate's approach, led by experts in obesity and nutrition science, aims to improve metabolic health and drive lasting results.

Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

Alto Pharmacy is a leading digital pharmacy established in 2015, focused on transforming the pharmacy industry through innovative technology and expert pharmacist care. The company aims to enhance the medication experience by providing a more convenient and affordable service, leveraging a mobile app and web portal for medication management and scheduled delivery. Alto has fulfilled over three million prescriptions and has expanded its services to twelve markets, emphasizing the critical role of pharmacists in the healthcare journey. With a strong commitment to customer satisfaction, Alto boasts an industry-leading Net Promoter Score, reflecting its dedication to improving healthcare services for patients.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Dialyze Direct is a healthcare company that specializes in providing staff-assisted home hemodialysis services for elderly patients suffering from End Stage Renal Disease. The company focuses on delivering customized and coordinated dialysis care through a team of registered nurses, dieticians, and social workers. By offering these services in a home setting, Dialyze Direct aims to improve patient outcomes while reducing overall healthcare costs. The approach not only alleviates the need for transportation but also helps minimize hospital readmissions, thereby enhancing the quality of life for geriatric patients.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs both in the United States and internationally. The company's commercial offerings include Sympazan, an oral soluble film formulation of clobazam for Lennox-Gastaut syndrome; Suboxone, a sublingual film that combines buprenorphine and naloxone for opioid dependence; and Zuplenz, an oral film formulation of ondansetron for nausea and vomiting related to chemotherapy and post-operative recovery. Additionally, Aquestive's proprietary pipeline features Libervant, a buccal film formulation of diazepam for epileptic seizures, and Exservan, an oral film formulation of riluzole for Amyotrophic Lateral Sclerosis. The company is also advancing products like AQST-108, a sublingual film formulation of epinephrine for anaphylaxis, and AQST-305, a sublingual film formulation of octreotide for acromegaly. Founded in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics is recognized for its proprietary technologies and collaborations with pharmaceutical partners to bring novel therapies to market.

Veran Medical Technologies, Inc. is a medical device company specializing in minimally invasive therapeutic devices for interventional oncology. Headquartered in St. Louis, Missouri, the company focuses on developing products that assist physicians in diagnosing diseases and delivering targeted therapies. Its offerings include the SPiNView thoracic navigation system, an electromagnetic device designed for the biopsy of solitary pulmonary nodules, and the ig4 IR System, which aids in performing biopsies and other procedures for the lungs, liver, and kidneys. Additionally, Veran Medical provides various instruments such as the vPad2 tracker device and the SPiNPerc hybrid diagnostic tool. The company's innovative solutions utilize advanced imaging technologies to create dynamic 3D maps of respiratory pathways, enhancing procedural planning and navigation, ultimately helping clinicians to expedite cancer diagnosis and treatment. Founded in 2003, Veran Medical Technologies is committed to improving patient outcomes through precision-guided interventions.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Establishment Labs, founded in 2004, is a medical technology company based in Alajuela, Costa Rica. It specializes in designing, manufacturing, and marketing silicone-filled breast and body shaping implants, primarily under the Motiva Implants brand. The company offers a wide range of breast implants with various surface, shape, size, base, and projection choices. Additionally, Establishment Labs provides Q Inside Safety Technology, a radio frequency identification transponder for implant data access, and Divina 3D imaging technology for surgical planning. Its products are sold through exclusive distributors and direct sales to plastic surgeons, hospitals, and clinics in over 80 countries worldwide. The company's manufacturing facilities adhere to strict FDA and ISO standards.

BioQ Pharma Incorporated is a specialty pharmaceutical company that develops and commercializes a range of ready-to-use infusible pharmaceuticals, focusing on post-surgical pain management, anesthesia, and sedation. The company offers products such as Ropivacaine for pain relief and Propofol for anesthesia, while also working on pipeline candidates in antibiotics and oncology. BioQ Pharma utilizes a proprietary unit-dose infusion system designed to enhance the efficiency, safety, and sterility of medication administration at the point of care. This innovative approach aims to address critical issues in infusion therapy, including medication errors and cost-effectiveness, ultimately improving patient quality of life. The company markets its products through partnerships in the U.S., Europe, China, and Taiwan, collaborating with notable firms in the pharmaceutical industry. Established in 2003 and based in San Francisco with an additional site in Gent, Belgium, BioQ Pharma was formerly known as BioQuiddity Incorporated until its name change in 2015.

BioQ Pharma Incorporated is a specialty pharmaceutical company that develops and commercializes a range of ready-to-use infusible pharmaceuticals, focusing on post-surgical pain management, anesthesia, and sedation. The company offers products such as Ropivacaine for pain relief and Propofol for anesthesia, while also working on pipeline candidates in antibiotics and oncology. BioQ Pharma utilizes a proprietary unit-dose infusion system designed to enhance the efficiency, safety, and sterility of medication administration at the point of care. This innovative approach aims to address critical issues in infusion therapy, including medication errors and cost-effectiveness, ultimately improving patient quality of life. The company markets its products through partnerships in the U.S., Europe, China, and Taiwan, collaborating with notable firms in the pharmaceutical industry. Established in 2003 and based in San Francisco with an additional site in Gent, Belgium, BioQ Pharma was formerly known as BioQuiddity Incorporated until its name change in 2015.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.